期刊
NEUROBIOLOGY OF AGING
卷 33, 期 8, 页码 1816-1828出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2011.09.040
关键词
P2X7; Familiar Alzheimer's disease; APP transgenic mice; GSK-3; alpha-secretase; APP; Amyloid plaques
资金
- MICINN [BFU2008-02699, BFU2005-06034, SAF2009-12249-CO2-02]
- CAM [S-SAL-0253-2006]
- Spanish Ion Channel Initiative (SICI) [CSD2008-00005]
- UCM-Santander Central Hispano Bank [911585-670]
- Fundacion Marcelino Botin
- SICI
- Juan de la Cierva Program
beta-amyloid (A beta) peptide production from amyloid precursor protein (APP) is essential in the formation of the beta-amyloid plaques characteristic of Alzheimer's disease. However, the extracellular signals that maintain the balance between nonpathogenic and pathologic forms of APP processing, mediated by alpha-secretase and beta-secretase respectively, remain poorly understood. In the present work, we describe regulation of the processing of APP via the adenosine triphosphate (ATP) receptor P2X7R. In 2 different cellular lines, the inhibition of either native or overexpressed P2X7R increased alpha-secretase activity through inhibition of glycogen synthase kinase 3 (GSK-3). In vivo inhibition of the P2X7R in J20 mice, transgenic for mutant human APP, induced a significant decrease in the number of hippocampal amyloid plaques. This reduction correlated with a decrease in glycogen synthase kinase 3 activity in J20 mice, increasing the proteolytic processing of APP through an increase in alpha-secretase activity. The in vivo findings presented here demonstrate for the first time the therapeutic potential of P2X7R antagonism in the treatment of familiar Alzheimer's disease (FAD). (C) 2012 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据